Protagonist Therapeutics develops peptide and small molecule medicines for inflammatory, blood and metabolic diseases. It last closed at $124.67 on Nov 17, down 0.13% on the day. The average 12-month price target from 7 analysts is $186.71 (+49.8% from the last close), with a high of $221.00 and a low of $160.00. Analyst consensus is Strong Buy, based on the latest ratings from 7 firms (7 buy, 0 hold, 0 sell).
Each firm's latest rating on PTGX in the past 90 days
Average 12-month target
$186.71
▲ 49.8% upside
Based on 7 analysts who set a price target on PTGX in the past 90 days. The average target is $186.71, with a high of $221.00 and a low of $160.00, compared with the last close of $124.67.
Low $160.00Avg $186.71High $221.00
Blue marker: last close $124.67
Highest target$221.00
Average target$186.71
Lowest target$160.00
Latest rating changes
HC Wainwright & Co.Target raised
Nov 6Buy$170 → $221
TD CowenMaintained
Oct 21Buy$160
UBSInitiated
Oct 12Buy$184
Leerink PartnersAssumed coverage
Oct 12Buy$190
BarclaysTarget raised
Sep 1Buy$153 → $180
Date
Firm
Action
Rating
Price target
Nov 6
HC Wainwright & Co.
Target raised
Buy
$170 → $221
Oct 21
TD Cowen
Maintained
Buy
$160
Oct 12
UBS
Initiated
Buy
$184
Oct 12
Leerink Partners
Assumed coverage
Buy
$190
Sep 1
Barclays
Target raised
Buy
$153 → $180
Loading…
Technical Analysis
PTGX · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend, nearing oversold
The stock is 10% below its 20 day and 12% below its 50 day average. It is 4% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 32), near oversold. The nearest support is the Pivot at $124.11, and the nearest resistance the Pivot R1 at $126.46.
Short trendBearish
Long trendBullish
MomentumWeak
StretchNear oversold
VolatilityNormal, 4.6%/day
Key levels
$160.8152 week high+29.0%
$140.47100 day average+12.7%
$139.4650 day average+11.9%
$138.82Swing high (Nov 12)+11.3%
$137.0520 day average+9.9%
$126.46Pivot R1+1.4%
$124.67Last close
$124.11Pivot−0.4%
$122.31Pivot S1−1.9%
$119.71200 day average−4.0%
$118.27Swing low (Jun 29)−5.1%
$77.0052 week low−38.2%
Indicators
RSI (14)
32.47
Weak, oversold below 30
Neutral
MACD
-3.18
Below its signal line
Bearish
Stochastic
10.5
Near the bottom of its range
Oversold
ADX (14)
23.5
Weak trend
Williams %R
-88.2
Oversold below −80, overbought above −20
Oversold
CCI (20)
-207.6
Oversold below −100, overbought above 100
Oversold
Rate of change
−11.1%
Change over 10 sessions
Bearish
ATR (14)
$5.79
Typical daily range, 4.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
Rising
Short trendBullish
Long trendNot enough history
MomentumFading
StretchNormal
VolatilityNormal, 9.2%/day
Key levels
$160.8152 week high+29.0%
$140.47100 day average+12.7%
$139.4650 day average+11.9%
$138.82Swing high (Nov 12)+11.3%
$137.0520 day average+9.9%
$126.46Pivot R1+1.4%
$124.67Last close
$124.11Pivot−0.4%
$122.31Pivot S1−1.9%
$119.71200 day average−4.0%
$118.27Swing low (Jun 29)−5.1%
$77.0052 week low−38.2%
Indicators
RSI (14)
46.54
Middle of its range
Neutral
MACD
5.07
Below its signal line
Bearish
Stochastic
12.4
Near the bottom of its range
Oversold
ADX (14)
33.5
Trending down
Williams %R
-92.5
Oversold below −80, overbought above −20
Oversold
CCI (20)
-173.2
Oversold below −100, overbought above 100
Oversold
Rate of change
−15.9%
Change over 10 sessions
Bearish
ATR (14)
$11.52
Typical daily range, 9.2% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200–
What happened before, for PTGX
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how PTGX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow PTGX usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How PTGX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2016.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PTGX is in one of them and how their past PTGX trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Protagonist Therapeutics
Protagonist Therapeutics is a drug discovery and development company based in Newark, California. It is developing medicines for inflammatory skin conditions, a rare blood disorder called polycythemia vera, and obesity. Its key candidates include Icotyde, a treatment for plaque psoriasis being developed with Johnson & Johnson, and rusfertide, an injectable therapy for polycythemia vera developed with Takeda. These medicines are intended for patients with these conditions, and its partners are large drugmakers.